One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial

By sjmartinez • June 7, 2023

Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023 Jun 5:ciad342. doi: 10.1093/cid/ciad342. Epub ahead of print. PMID: 37279602.

Tags: camostat, covid-19, Infectious Diseases, outpatient, phase 2, Publications, SARS-CoV-2

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial

Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin[...]

Mirtazapine reduces hypothetical methamphetamine demand in humans

Rush CR, Santos GM, McMahan VM, Fraser A, Clark J, Luna Marti X, Walker JE, Shoptaw S, Coffin PO. Mirtazapine reduces hypothetical methamphetamine demand in[...]

A systematic nomenclature for mpox viruses causing outbreaks with sustained human-to-human transmission

Ruis C, Lusamaki E, O'Toole A, Otieno JR, Colquhoun R, Roemer C, Wawina-Bokalanga T, Tshiani-Mbaya O, Jansen D, Makangara JC, Agrawal A, Abu-Raddad LJ, Ahuka-Mundeke[...]